Departments of Pharmacology, Tulane University School of Medicine, Tulane Avenue, New Orleans, LA, USA.
Sci Rep. 2012;2:539. doi: 10.1038/srep00539. Epub 2012 Jul 27.
Altered death receptor signaling and resistance to subsequent apoptosis is an important clinical resistance mechanism. Here, we investigated the role of death receptor resistance in breast cancer progression. Resistance of the estrogen receptor alpha (ER)-positive, chemosensitive MCF7 breast cancer cell line to tumor necrosis factor (TNF) was associated with loss of ER expression and a multi-drug resistant phenotype. Changes in three major pathways were involved in this transition to a multidrug resistance phenotype: ER, Death Receptor and epithelial to mesenchymal transition (EMT). Resistant cells exhibited altered ER signaling, resulting in decreased ER target gene expression. The death receptor pathway was significantly altered, blocking extrinsic apoptosis and increasing NF-kappaB survival signaling. TNF resistance promoted EMT changes, resulting in a more aggressive phenotype. This first report identifying specific mechanisms underlying acquired resistance to TNF could lead to a better understanding of the progression of breast cancer in response to chemotherapy treatment.
改变的死亡受体信号和随后的细胞凋亡抵抗是一个重要的临床耐药机制。在这里,我们研究了死亡受体抵抗在乳腺癌进展中的作用。雌激素受体α (ER)阳性、化疗敏感的 MCF7 乳腺癌细胞系对肿瘤坏死因子 (TNF)的耐药性与 ER 表达缺失和多药耐药表型有关。这一转变为多药耐药表型涉及三个主要途径的变化:ER、死亡受体和上皮间质转化 (EMT)。耐药细胞表现出 ER 信号的改变,导致 ER 靶基因表达减少。死亡受体途径发生显著改变,阻断了外在凋亡并增加了 NF-κB 存活信号。TNF 耐药性促进 EMT 改变,导致更具侵袭性的表型。这是第一个鉴定 TNF 获得性耐药的具体机制的报告,它可以帮助我们更好地理解乳腺癌对化疗治疗的反应进展。